NorthWest Biotherapeutics Inc (NWBO)

[Flexroy]

Aivita? Their drug failed

AV-GBM1 did not improve OS. LL is not associated with this study. The doctor is Hillman.

https://jitc.bmj.com/content/9/Suppl_2/A1001

"comparable standard therapy arms. PFS from the first injection is 8.3 months, which is 51% and 107% longer than reported in two randomized trials with comparable standard therapy arms. OS was 72% at 12 months, but dropped to 54% at 14.6 months; median OS is 16.0 months.

Conclusions Patent-specific AV-GBM-1 was reliably manufactured and distributed for administration. AV-GBM-1 produced minimal toxicity. PFS was very encouraging but did not translate into OS, perhaps because of discontinuation of treatment after 8 months"